Product news from 09/09 News Brief

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

September 9, 2005

6:17 pm

Takeda Pharmaceuticals North America announced that the FDA has approved the New Drug Application for ACTOplus Met for the treatment of type 2 diabetes.

Cephalon has entered into an agreement with McNeil Consumer & Specialty Pharmaceuticals to co-promote Attenace (modafinil) Tablets. Attenace is Cephalon’s proprietary dosage form of modafinil, which is awaiting FDA approval for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.

From Our Partners

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.

Partner Content

The new brand.com experience

How healthcare manufacturers can improve customer engagement, drive high-value activity and inform future strategy with conversational AI.

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

Partner Content

Shifting market trends are transforming how pharma marketers find, target and engage with patients and providers

The Healthcare Marketers Trend Survey shows that, as far as channel usage goes, more growth occurred in newer tactics like non-linear video and streaming audio than in some of the more traditional ones.

A Big C Shift: Rebranding cancer to reflect advances in oncology

Partner Content

A Big C Shift: Rebranding cancer to reflect advances in oncology

Pivoting people’s perception of the disease to match the realities of treatment.